Anzeige
Erschienen in:
19.11.2018 | Melanoma
Validation of a Nomogram for Non-sentinel Node Positivity in Melanoma Patients, and Its Clinical Implications: A Brazilian–Dutch Study
Erschienen in: Annals of Surgical Oncology | Ausgabe 2/2019
Einloggen, um Zugang zu erhaltenAbstract
Background
Non-sentinel node (NSN) positivity impacts the prognosis of melanoma patients; however, the benefits of completion lymph node dissection in patients with positive sentinel nodes (SNs) are limited.
Objective
We aimed to present a predictive nomogram for NSN positivity in melanoma patients with a positive SN biopsy.
Methods
This retrospective analysis from patients who underwent SN biopsy in a Brazilian institution from 2000 to 2015 was used for the construction and internal validation of the nomogram. This nomogram was then externally validated in a cohort of Dutch patients.
Results
The Brazilian cohort comprised 1213 patients, with a mean follow-up of 5.11 years. Breslow thickness (odds ratio [OR] 1.170, 95% confidence interval [CI] 1.043–1.314]; p = 0.008), number of positive SNs (OR 1.092, 95% CI 1.034–1.153; p = 0.001), and largest diameter of the metastatic deposit (OR 3.217, 95% CI 1.551–6.674; p = 0.002) were statistically significant for NSN positivity. Internal validation was performed using a bootstrapping technique. A good performance was observed (Brier score 0.097) and an excellent power of discrimination was achieved (area under the curve [AUC] 0.822). The nomogram was then applied to the Dutch cohort, and its overall performance (Brier score 0.085), calibration (Hosmer–Lemeshow goodness-of-fit test; p = 0.198), and discriminatory power (AUC 0.752, 95% CI 0.615–0.890) were all adequate.
Conclusions
We presented a nomogram for assessing NSN probability that should not only be used for surgical considerations but also for risk stratification and clinical decisions. Internal validation has shown that this is an adequate model, while external validation increases the model’s reliability and suggests that it can be globally incorporated.